'Low-dose IL-2 balances Tfh, Tph, and Treg cells in myasthenia gravis (MG), by increasing Treg cells and reducing Tfh and Tph cell populations in patients. The results provide in vitro evidence for the use of IL-2 as a potential therapeutic in MG.'
https://onlinelibrary.wiley.com/doi/full/10.1002/eji.202451268